A new study conducted as part of the COST Action Precision-BTC-Network and led by Prof. Jesper Andersen provides important new insights into iCCA, one of the most aggressive forms of liver cancer.

The research reveals how autonomous IL-6 signaling within the tumor reshapes tumor biology at multiple levels. It drives transcriptional and metabolic reprogramming in cancer cells, while profoundly altering the tumor microenvironment and the immune response.

Importantly, the study identifies new therapeutic vulnerabilities, particularly related to metabolic pathways, and highlights new opportunities for targeted treatment strategies.

By integrating advanced approaches, such as patient-derived models, high-throughput drug screening, and spatial transcriptomics, this work offers a comprehensive view of the mechanisms underlying tumor progression.

The results underscore the value of COST-driven international collaboration for advancing precision medicine approaches in bile duct cancers.

READ THE STUDY HERE